USMLE Step 2 Quiz
Practice Solid Tumor Oncology And Cancer Screening in USMLE Step 2 with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.
Question 1 / 20
0 of 20 answered
A 58-year-old man with a 35-pack-year smoking history presents for an annual physical examination. He quit smoking 10 years ago. He is asymptomatic and feels well. His physical examination is unremarkable. He is interested in cancer screening.
What is the most appropriate screening recommendation for lung cancer in this patient?
This quiz focuses on Solid Tumor Oncology And Cancer Screening, giving you a quick way to practice the rules, question types, and explanations that matter most for USMLE Step 2.
Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.
A 58-year-old man with a 35-pack-year smoking history presents for an annual physical examination. He quit smoking 10 years ago. He is asymptomatic and feels well. His physical examination is unremarkable. He is interested in cancer screening.
What is the most appropriate screening recommendation for lung cancer in this patient?
Explanation: The US Preventive Services Task Force (USPSTF) recommends annual screening for lung cancer with low-dose computed tomography (LDCT) in adults aged 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years. This patient is 58 years old, has a 35-pack-year history, and quit 10 years ago, meeting all criteria for screening. Chest X-ray and sputum cytology have not been shown to reduce mortality and are not recommended for screening.
A 45-year-old asymptomatic woman with no significant family history of cancer presents for a routine health maintenance visit. She asks about appropriate cancer screening.
According to current guidelines, which of the following is the most appropriate recommendation for colorectal cancer screening for this patient?
Explanation: Major US guidelines (including the USPSTF and American Cancer Society) now recommend starting colorectal cancer screening for average-risk individuals at age 45. Colonoscopy every 10 years is a primary screening modality. While other options like annual FIT or flexible sigmoidoscopy are acceptable alternatives, initiating screening at age 45 is the current standard of care. Delaying screening until age 50 is based on outdated recommendations.
A 57-year-old African American man with no urinary symptoms asks about screening for prostate cancer. His father was diagnosed with prostate cancer at age 70. He wants to know if he should be tested.
What is the most appropriate recommendation regarding prostate cancer screening for this patient?
Explanation: For men aged 55 to 69, the USPSTF recommends that the decision to undergo PSA-based screening for prostate cancer should be an individual one. This patient is at higher risk due to his age, African American race, and family history. The most appropriate approach is to engage in shared decision-making, discussing the potential benefits (small reduction in mortality) and harms (false positives, overdiagnosis, complications of biopsy and treatment) of screening before ordering a PSA test.
A 28-year-old woman presents for a well-woman visit. Her last Pap test was at age 25 and was normal. She has been in a monogamous relationship for 5 years and has no gynecologic complaints.
Which of the following is the most appropriate screening for cervical cancer at this visit?
Explanation: Current guidelines recommend cervical cancer screening with cytology (Pap test) alone every 3 years for women aged 21-29. Since this patient's last normal Pap test was 3 years ago at age 25, she is due for screening. HPV co-testing and primary HPV testing are not recommended as primary screening strategies for women under age 30.
A 65-year-old man is diagnosed with a large, locally advanced rectal adenocarcinoma. The tumor is located 6 cm from the anal verge. Staging MRI shows invasion through the muscularis propria into the perirectal fat (T3) with several enlarged regional lymph nodes (N1). There is no evidence of distant metastatic disease on CT scan.
What is the most appropriate initial step in this patient's treatment plan?
Explanation: For locally advanced rectal cancer (Stage II-III), the standard of care is neoadjuvant chemoradiation. This approach helps to downstage the tumor, increasing the likelihood of a complete surgical resection with negative margins (R0 resection) and improving the chance of sphincter preservation. It has also been shown to reduce local recurrence rates compared to postoperative radiation. Surgery first is incorrect for T3/N1 disease. Palliative therapy is not indicated for potentially curable disease.
A 55-year-old postmenopausal woman underwent a lumpectomy and sentinel lymph node biopsy for a 1.5-cm invasive ductal carcinoma of the breast. Pathology reveals the tumor is estrogen receptor-positive, progesterone receptor-positive, and HER2-negative. The sentinel lymph nodes are negative for metastasis. She is scheduled to receive adjuvant radiation therapy.
In addition to radiation therapy, which of the following is the most appropriate adjuvant systemic therapy for this patient?
Explanation: This patient has hormone receptor (HR)-positive, HER2-negative breast cancer. For postmenopausal women, an aromatase inhibitor (e.g., anastrozole, letrozole, exemestane) is the preferred adjuvant endocrine therapy as it has shown superior efficacy compared to tamoxifen. Tamoxifen is typically used for premenopausal women. Trastuzumab is an anti-HER2 therapy and is not indicated. Doxorubicin is a chemotherapy agent, which may or may not be indicated depending on other risk factors (e.g., recurrence score), but endocrine therapy is standard for all HR-positive tumors.
A 70-year-old man presents with a 2-week history of painless jaundice, dark urine, and clay-colored stools. He has also noted a 10-lb unintentional weight loss over the past 2 months. Physical examination reveals scleral icterus and a non-tender, palpable gallbladder in the right upper quadrant.
Which of the following is the most likely diagnosis?
Explanation: The classic presentation of painless obstructive jaundice with a palpable, non-tender gallbladder (Courvoisier sign) and weight loss is highly suggestive of pancreatic adenocarcinoma at the head of the pancreas causing obstruction of the common bile duct. Acute cholangitis would present with fever and abdominal pain (Charcot's triad). Choledocholithiasis typically causes painful jaundice. Hepatocellular carcinoma is less likely to cause this specific constellation of symptoms unless very advanced.
A 62-year-old man with a 40-pack-year smoking history is found to have a 2-cm spiculated nodule in the right upper lobe on a chest CT scan. A subsequent biopsy confirms non-small cell lung cancer. The CT scan does not show any enlarged mediastinal lymph nodes or obvious metastatic disease.
Which of the following is the most appropriate next test for staging before determining resectability?
Explanation: For a newly diagnosed, potentially resectable non-small cell lung cancer, a PET/CT scan is the most important staging investigation. It is used to assess for mediastinal lymph node involvement and distant metastatic disease (e.g., in the bones, liver, adrenal glands), which are crucial for determining operability and treatment planning. Brain MRI is also part of standard staging but PET/CT provides comprehensive systemic staging. Bone scan and abdominal ultrasound have been largely replaced by the more sensitive whole-body PET/CT for initial staging.
A 48-year-old woman presents with a new, firm, non-tender, 2-cm lump in the upper outer quadrant of her left breast discovered on self-exam. She has no family history of breast cancer. A diagnostic mammogram reveals a high-density, spiculated mass with microcalcifications corresponding to the palpable lump.
What is the most appropriate next step in management?
Explanation: A suspicious palpable mass with corresponding malignant-appearing mammographic findings requires tissue diagnosis. Core needle biopsy is the standard of care as it provides histologic architecture, which is necessary to differentiate in-situ from invasive carcinoma and allows for hormone receptor (ER, PR) and HER2 testing. Fine-needle aspiration only provides cytologic information and has a higher non-diagnostic rate. Excisional biopsy is a surgical procedure that is generally performed after a tissue diagnosis is established. Observation is inappropriate for a highly suspicious lesion.
A 45-year-old woman is diagnosed with a 1-cm, clinically node-negative invasive breast cancer. Her axilla is non-tender and without palpable adenopathy. She is scheduled for a lumpectomy.
Which of the following procedures is most appropriate to surgically stage the axilla?
Explanation: For patients with early-stage invasive breast cancer and a clinically negative axilla (no palpable lymph nodes), sentinel lymph node biopsy (SLNB) is the standard procedure for staging. It accurately identifies whether the cancer has spread to the initial draining lymph nodes while avoiding the significant morbidity (e.g., lymphedema, nerve injury) associated with a full axillary lymph node dissection. Axillary dissection is reserved for patients with positive sentinel nodes (in some cases) or clinically positive nodes. FNA is used for suspicious nodes, not for staging a clinically negative axilla.
A 55-year-old woman undergoes lumpectomy and sentinel lymph-node biopsy for a 1.2-cm, grade II invasive ductal carcinoma of the left breast. The tumor is estrogen-receptor positive, progesterone-receptor positive, and HER2 negative. Margins are clear, and 2 sentinel nodes are negative. She is otherwise healthy.
Which of the following is the most appropriate next step in management to guide the need for adjuvant chemotherapy?
Explanation: When managing early-stage breast cancer, the key decision point after surgery is determining which patients need chemotherapy versus endocrine therapy alone. For hormone receptor-positive, HER2-negative tumors like this one, genomic testing helps stratify risk and guide treatment decisions. The 21-gene recurrence score assay (Oncotype DX) analyzes the expression of specific genes to predict both recurrence risk and chemotherapy benefit. For this patient with a T1 (1.2 cm), node-negative, hormone receptor-positive tumor, this test is specifically indicated to determine whether she needs chemotherapy or can be managed with endocrine therapy alone. The assay provides a recurrence score that categorizes patients into low, intermediate, or high-risk groups, directly informing treatment decisions. Option B is premature because you haven't established that this patient needs chemotherapy. While she may benefit from it, the genomic testing should guide this decision rather than automatically starting aggressive treatment. Option C assumes she's low-risk without proper risk stratification - endocrine therapy alone may be appropriate, but only after confirming low recurrence risk through testing. Option D addresses radiation therapy, which is a separate decision from systemic therapy and doesn't help determine chemotherapy need. For USMLE Step 2, remember that modern breast cancer management emphasizes personalized medicine. When you see a hormone receptor-positive, HER2-negative, node-negative breast cancer case, think genomic testing first before jumping to chemotherapy decisions. The 21-gene assay has become standard of care for precisely this clinical scenario.
A 68-year-old man who smoked 45 pack-years quit 10 years ago. He has no pulmonary symptoms and a normal physical examination. He requests advice about cancer prevention.
Which screening test is recommended for this patient?
Explanation: When you encounter questions about cancer screening, focus on evidence-based guidelines from major medical organizations. Lung cancer screening represents one of the most important preventive interventions for high-risk patients. This patient meets all criteria for lung cancer screening: he's between ages 50-80, has a significant smoking history (≥20 pack-years), and quit within the last 15 years. The U.S. Preventive Services Task Force recommends annual low-dose CT (LDCT) screening for such patients because large randomized trials demonstrated a 20% reduction in lung cancer mortality compared to no screening. Choice A is correct because LDCT is the only screening method proven to reduce lung cancer deaths. It can detect small nodules before they become symptomatic, when treatment is most effective. Choice B is wrong because chest X-rays lack sufficient sensitivity to detect early-stage lung cancers. Multiple studies showed no mortality benefit from chest radiograph screening. Choice C is incorrect because sputum cytology has poor sensitivity for lung cancer detection and is not recommended by any major guideline. It misses most early-stage cancers. Choice D represents a dangerous misconception. While smoking cessation reduces lung cancer risk over time, former smokers remain at elevated risk for decades. The 15-year cutoff in screening guidelines reflects when risk approaches that of never-smokers, but this patient quit only 10 years ago. Key takeaway: Memorize lung cancer screening criteria (age 50-80, ≥20 pack-years, quit ≤15 years ago) and remember that LDCT is the only evidence-based screening method. The USMLE frequently tests knowledge of preventive care guidelines.
A 35-year-old man presents for a routine visit. His father was diagnosed with colorectal cancer at age 45. The patient is asymptomatic and has no other risk factors.
What is the most appropriate colorectal-cancer screening strategy for this patient?
Explanation: When you encounter colorectal cancer screening questions, focus on family history as a key risk stratification factor. Patients with a first-degree relative diagnosed with colorectal cancer need earlier and more intensive screening than the general population. For this 35-year-old with a father diagnosed at age 45, current guidelines recommend starting colonoscopy at age 40 (10 years before the relative's diagnosis age) or at the current age if already past 40. Since he's 35, he should start screening now. The screening interval should be every 5 years due to his increased risk, making option A correct. Option B is wrong because fecal immunochemical testing (FIT) is less sensitive than colonoscopy and inappropriate for high-risk patients. While FIT is acceptable for average-risk screening, patients with significant family history need the superior detection and therapeutic capability of colonoscopy. Option C represents average-risk screening guidelines (start at 50, repeat every 10 years) and fails to account for his family history. This approach would miss the critical window where his increased genetic risk becomes relevant. Option D suggests CT colonography, which while effective for detection, cannot remove polyps if found. Given his high-risk status, the gold standard of colonoscopy with immediate polypectomy capability is preferred over imaging-only methods. Study tip: Remember the "10-year rule" for family history - start screening 10 years before the age when the relative was diagnosed, but not before age 40. High-risk patients always need colonoscopy, not alternative screening methods.
A 62-year-old man undergoes right hemicolectomy for colon adenocarcinoma. Pathology shows T3N1M0 disease with 2 of 18 lymph nodes positive and clear margins. He has recovered well from surgery.
Which adjuvant therapy is most appropriate to improve disease-free survival?
Explanation: When you encounter colon cancer staging questions, focus on the TNM classification to determine appropriate adjuvant therapy. This patient has T3N1M0 disease - indicating tumor invasion through the muscularis propria (T3) with 1-3 regional lymph nodes involved (N1) and no distant metastases (M0). This represents Stage IIIB disease. For Stage III colon cancer (any T with N1-2, M0), standard of care is adjuvant chemotherapy with an oxaliplatin-based regimen like FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) for 6 months. This combination significantly improves disease-free and overall survival compared to surgery alone, with evidence showing approximately 20% reduction in recurrence risk. Choice A is correct because oxaliplatin-based chemotherapy is the established standard for node-positive colon cancer. Choice B (observation alone) would be appropriate only for Stage I-II disease with favorable features, but this patient's positive lymph nodes mandate adjuvant treatment. Choice C (pelvic radiation) is used primarily for rectal cancer, not colon cancer, since colon cancer rarely benefits from radiation therapy due to bowel mobility and toxicity concerns. Choice D (cetuximab monotherapy) is incorrect because cetuximab is reserved for metastatic disease and requires KRAS/RAS wild-type status for efficacy. Remember this key principle: node-positive colon cancer (Stage III) always requires adjuvant chemotherapy unless contraindicated. The presence of even one positive lymph node dramatically changes prognosis and treatment approach from observation to active systemic therapy.
A 48-year-old man from China has chronic hepatitis B infection without cirrhosis. His alanine aminotransferase level is normal, and ultrasound done 1 year ago was unremarkable.
Which of the following is the most appropriate hepatocellular-carcinoma surveillance strategy?
Explanation: When you encounter hepatitis B surveillance questions, remember that risk stratification drives the approach. Chronic hepatitis B patients have increased hepatocellular carcinoma (HCC) risk even without cirrhosis, especially those from high-prevalence areas like China. The correct answer is A because current guidelines recommend ultrasound every 6 months for chronic hepatitis B patients regardless of cirrhosis status. This patient's Asian ethnicity, chronic infection, and age over 40 place him in a high-risk category requiring active surveillance. Ultrasound is cost-effective, widely available, and has reasonable sensitivity for detecting early HCC. Option B is inadequate because alpha-fetoprotein (AFP) alone has poor sensitivity and specificity for HCC screening. Many early HCCs don't elevate AFP, and yearly intervals are too long for effective surveillance. Option C uses inappropriate timing and modality. While triphasic CT has excellent sensitivity, it's expensive and exposes patients to radiation. Two-year intervals are far too long for cancer surveillance - tumors can develop and progress significantly in this timeframe. Option D reflects outdated thinking. Older guidelines focused surveillance only on cirrhotic patients, but we now know that chronic hepatitis B carries HCC risk even in non-cirrhotic livers, particularly in certain populations. For Step 2, remember that hepatitis B surveillance is more aggressive than hepatitis C surveillance. Asian patients with chronic hepatitis B warrant surveillance regardless of liver enzyme levels or cirrhosis status, unlike hepatitis C where cirrhosis typically triggers surveillance initiation.
A 55-year-old woman with no family history of pancreatic cancer and no known genetic syndrome recently developed type 2 diabetes mellitus. She quit smoking 5 years ago after a 20-pack-year history and asks if she should be screened for pancreatic cancer like her friend who was recently diagnosed.
Which recommendation is most appropriate?
Explanation: When you encounter questions about cancer screening, always consider whether the patient meets established criteria for high-risk populations. Pancreatic cancer screening is only recommended for very specific high-risk groups, not for the general population. Option A is correct because this patient has average risk for pancreatic cancer. Current guidelines recommend screening only for individuals with strong family history (typically two or more first-degree relatives with pancreatic cancer), known genetic syndromes (like BRCA2, Lynch syndrome, or Peutz-Jeghers), or specific hereditary pancreatitis mutations. Her smoking history and new-onset diabetes, while concerning symptoms that warrant clinical attention, don't qualify her for routine screening protocols. Option B is wrong because annual CT screening isn't recommended for average-risk individuals and would expose her to unnecessary radiation and potential false positives. Option C is incorrect because endoscopic ultrasound screening is reserved for high-risk patients meeting specific genetic or familial criteria - this intensive approach isn't justified for her risk profile. Option D is flawed because CA 19-9 has poor sensitivity and specificity for early pancreatic cancer detection and produces too many false positives in average-risk populations. Her new-onset diabetes at age 55 could potentially be an early sign of pancreatic cancer, but this alone doesn't warrant screening - it warrants clinical evaluation if she develops other concerning symptoms like weight loss, abdominal pain, or jaundice. Remember: Cancer screening recommendations are risk-stratified. Always identify whether patients meet high-risk criteria before recommending intensive screening protocols that aren't indicated for average-risk individuals.
A 60-year-old man underwent radical prostatectomy for Gleason 3 + 4 localized prostate cancer 4 years ago. His postoperative PSA had been undetectable, but two recent measurements are 0.2 ng/mL and 0.4 ng/mL, 3 months apart. CT and bone scan show no metastases.
What is the most appropriate next step in management?
Explanation: When you encounter PSA recurrence after radical prostatectomy, think systematically about timing, risk factors, and the window for curative treatment. This patient demonstrates biochemical recurrence - two consecutive PSA rises above 0.2 ng/mL after previously undetectable levels. The correct approach is A) salvage external-beam radiotherapy to the prostate bed. This patient has several favorable factors for salvage radiation: relatively low PSA levels (0.4 ng/mL), intermediate-grade cancer (Gleason 3+4), no evidence of metastases, and PSA doubling time allowing treatment within the curative window. Salvage radiotherapy is most effective when PSA is under 1.0 ng/mL and offers the best chance for cure in biochemical recurrence. B) androgen-deprivation therapy is palliative, not curative, and reserved for patients with metastatic disease or those unsuitable for radiation. Starting lifelong hormonal therapy now would forfeit the chance for cure. C) observation until PSA reaches 2.0 ng/mL is inappropriate because salvage radiation effectiveness decreases significantly as PSA rises. Waiting reduces cure rates and may allow progression beyond the treatable window. D) transrectal biopsy is unnecessary and potentially harmful. The prostate bed cannot be biopsied after prostatectomy, and imaging already ruled out distant disease. Rising PSA after undetectable levels confirms recurrence. Key strategy: For post-prostatectomy PSA recurrence, remember the "strike while the iron is hot" principle - salvage radiation works best early, typically when PSA is under 1.0 ng/mL. Don't wait for higher levels or waste time on unnecessary procedures.
A 70-year-old man with coronary artery disease is found incidentally to have a 2.3-cm enhancing solid mass in the upper pole of the right kidney on CT performed for hematuria. He has an excellent performance status but wishes to minimize operative risk.
Which management strategy is most appropriate?
Explanation: When you encounter a renal mass on imaging, you need to consider the size, patient factors, and treatment goals to determine the optimal management approach. Small renal masses (typically <4 cm) in elderly patients with significant comorbidities often warrant careful consideration of conservative management. Active surveillance (A) is the most appropriate choice here because this 70-year-old patient has coronary artery disease and specifically wants to minimize operative risk. A 2.3-cm renal mass has a relatively slow growth rate and low metastatic potential, especially in elderly patients. Active surveillance involves serial imaging every 3-6 months initially, then annually if stable, allowing intervention only if the mass grows significantly or becomes symptomatic. Partial nephrectomy (B) would be appropriate for a younger, healthier patient or if the mass showed aggressive features, but this patient's age and comorbidities make surgery unnecessarily risky for a small, likely indolent mass. Radical nephrectomy with adjuvant therapy (C) is excessive for a small renal mass - radical nephrectomy is typically reserved for larger masses (>7 cm) or those involving critical structures, and adjuvant tyrosine kinase inhibitors aren't standard for localized disease. Percutaneous thermal ablation with interleukin-2 (D) combines an invasive procedure with systemic therapy that has significant toxicity - interleukin-2 is rarely used due to its severe side effects. Remember: For small renal masses in elderly patients with comorbidities, active surveillance is often the safest initial approach. The key is matching treatment intensity to patient life expectancy and functional status.
A 27-year-old woman carries a confirmed pathogenic BRCA1 mutation. She is not pregnant and has not had previous breast imaging.
Which breast-cancer screening strategy is most appropriate for her current risk profile?
Explanation: When you encounter questions about BRCA mutation carriers, remember that these patients have dramatically elevated breast cancer risk (up to 87% lifetime risk for BRCA1) and require intensive, early screening protocols that differ significantly from average-risk women. For BRCA1 mutation carriers, current guidelines recommend starting annual breast MRI at age 25-30 (or 10 years earlier than the youngest affected family member). MRI is superior to mammography for detecting cancers in young, high-risk women because it's more sensitive in dense breast tissue and doesn't rely on architectural distortion that develops with age. Adding mammography starting at age 30 captures microcalcifications that MRI might miss, providing complementary detection methods. Answer A is correct because it follows evidence-based guidelines: early MRI screening captures the peak risk period for BRCA1 carriers (often in their 30s-40s), while adding mammography at 30 provides comprehensive surveillance. Answer B fails because mammography alone has poor sensitivity in young, dense breasts typical of BRCA carriers and misses the critical early detection window. Answer C is inadequate since self-examination has no proven mortality benefit and delays potentially life-saving early detection in this ultra-high-risk population. Answer D represents an extreme approach that, while effective for risk reduction, isn't the question's focus on screening strategy and may not align with the patient's preferences for breast preservation. For USMLE Step 2, remember that BRCA carriers need intensified, early screening starting in their twenties—think "MRI first, mammography added later" for these high-risk patients.
A 36-year-old woman with a BRCA1 mutation has completed childbearing. Physical examination and baseline imaging are normal.
Which risk-reduction strategy offers the greatest decrease in ovarian and fallopian-tube cancer mortality for this patient?
Explanation: When you encounter questions about hereditary cancer syndromes like BRCA1 mutations, focus on the most effective risk-reduction interventions. BRCA1 carriers have a 39-46% lifetime risk of ovarian cancer and elevated fallopian tube cancer risk, making aggressive prevention crucial. Prophylactic bilateral salpingo-oophorectomy (choice A) is the gold standard for BRCA1 carriers who have completed childbearing. This procedure reduces ovarian cancer risk by 85-95% and fallopian tube cancer risk by nearly 100%. Current guidelines recommend this surgery by age 35-40 for BRCA1 carriers, making "now or by age 40" perfectly appropriate timing for this 36-year-old patient. Choice B (transvaginal ultrasound with CA-125) represents screening rather than prevention. These methods have poor sensitivity for early ovarian cancer detection and don't significantly reduce mortality in high-risk women. Choice C (oral contraceptives) does provide some ovarian cancer risk reduction (about 50% after 5+ years of use), but this protection is far less than surgical removal and doesn't address fallopian tube cancer risk. Choice D (levonorgestrel IUD) primarily reduces endometrial cancer risk and has minimal impact on ovarian or fallopian tube cancer. Remember that for hereditary cancer syndromes, surgical prophylaxis typically offers the greatest mortality benefit when patients have completed childbearing. The key distinction is between risk reduction (prevention) versus surveillance (early detection) - prevention through organ removal is almost always superior for high-penetrance genetic mutations.